Film creditsA formula is also an ecosystem.
Microbial Material Systems is a proposed programme connecting ingredient behaviour, preservation evidence and the conditions under which a microbial observation becomes useful.
Proposed programme | Study scope, qualified delivery and funding to be agreed.
Making microbial behaviour part of the development decision.
Locate the uncertainty that matters to development.
A new film former, fermentation-derived ingredient or luxury refill concept can change more than the feel of a formulation. It changes the matrix in which a microbiological observation is made. The opportunity for Bio is to investigate those interfaces with enough precision that an application team can decide what to compare, which method to commission and what result would matter. This proposed programme would begin with the buyer’s formula and intended use, then build an evidence-led question that a qualified laboratory could answer without assuming an attractive ingredient story has already established product performance.
Examine the development decision
A formula is also an ecosystem.
Open the sequence to examine what a development decision needs.
Identify the exact preparation, its source, and the properties a second laboratory must be able to reproduce.
Explanatory geometry · no simulated or measured performance
Separate the product from the test.
Keep each observation attached to its preparation.
A count, inhibition curve or sequencing profile is the output of a particular preparation and measurement process. It carries information about organisms, extraction, recovery and observation time as well as the material being studied. FDA’s cosmetics method provides an analytical foundation; it is not a commercial endorsement of Bio (Huang et al., 2024). A useful commissioning record would preserve the sample identity, matrix, sampling location and method version. It would also distinguish the company’s hypothesis from the external evidence that motivated it. That distinction lets collaborators challenge a proposed study before committing samples or money.
Building around three commercially useful questions.
Separate three questions before selecting the study.
The first question is preservation compatibility: does a material change how a finished formula and its preservation system should be evaluated? The second is method compatibility: can organisms or molecular signals be recovered and interpreted from that particular matrix? The third is interface behaviour: how do a film, package or conditioned surface affect attachment and subsequent observation? These are connected questions, but their endpoints are different. A brand considering a refill is making a different decision from an ingredient supplier preparing a technical dossier. The programme would scope those decisions separately and price only work that has qualified delivery capacity.
The formula changes the observation.
Investigate the relationship between formulation, phase availability, sample recovery and interpretable microbial evidence.
Using models to expose the missing measurement.
See which count and recovery information is missing.
A log reduction is a compact description of two recoverable counts; it is not a complete definition of safety. The expression below shows why starting burden, sampling time and recovery all matter. A result below the method’s quantification limit must retain that limit rather than become an exact zero. The public catalogue for ISO 11930 identifies preservation-evaluation scope, while its licensed criteria require separate access (ISO, 2019). Bio’s model would help a sponsor ask whether its planned data can distinguish a material effect from a recovery artefact before choosing a larger comparison.
A measured count change can support a comparison only when its recovery and time basis are explicit.
- Logarithmic reduction at specified observation timedimensionless
- Initial recoverable countCFU g⁻¹ or CFU mL⁻¹
- Recoverable count after specified timesame units as N_0
- Observation timeh or d
Model conditions. Both counts use compatible, suitable recovery methods and the same basis. Counts must be positive; censored results retain limits. This descriptive relation supplies no preservation acceptance criterion.
Change the conditions · examine the reference
The total is not the available fraction.
Change pH and phase volume. See how a defined neutral species can redistribute even when total loading stays constant.
The data, equations and controls remain available below if 3D cannot load.
Defined model · illustrative conditions
Move a control to compare the selected condition with the defined reference curve.
Separate total loading from phase-specific concentration before defining a functional comparison.
The defined comparison
Hypothetical monoprotic weak acid: pKₐ = 4.8, neutral-species partition ratio K = [HA]oil/[HA]water = 10, total 1 mmol per litre of whole formulation. Only neutral HA partitions into oil; phase volumes are additive and activities ideal. No micelles, adsorption, binding or non-equilibrium behaviour. Phase shares refer to solute mass, not liquid volume. This reference does not predict preservation efficacy, microbial safety or delivery to skin.
Inspect the calculated values
Calculation grid, not measured observations. Inputs and assumptions are stated above.
| Aqueous pH / dimensionless | Aqueous neutral solute | Aqueous ionised solute | Neutral solute in oil |
|---|
Let microbiome research sharpen the question.
Use the biological setting to refine interpretation.
Pinto et al. (2021) studied specified organisms and preservative preparations in vitro; Wang et al. (2025) developed a defined microecology model. Neither establishes a human benefit for a Bio ingredient. Their value here is methodological: the biological setting and preparation should match the question being asked. A proposed microbiome-aware study would state which community or organism is represented, which response is measured and what cannot be inferred. Human outcomes would require a separately qualified study and appropriate oversight. The immediate commercial opportunity is a better experimental rationale, not a broad promise to repair someone’s microbiome.
Turning the science into a deliverable.
Define an output an application team can inspect.
The initial offer could be an application-specific decision brief containing a preparation map, method suitability questions, comparator rationale and a quotation-ready study outline. A subsequent externally delivered comparison would require an accountable microbiologist, appropriate facilities, agreed sample handling and explicit acceptance criteria. An ingredient business might use that package to decide whether a formulation compatibility claim is worth investigating. A beauty developer might use it to select the first test for a changed packaging format. Each deliverable should answer the sponsor’s decision and include negative or inconclusive findings where they affect the next commitment.
Earn the next headline through a reproducible comparison.
Connect ambition with an accountable first experiment.
A qualified university collaboration would be worth pursuing when the partner brings a method or biological model that the question genuinely needs. An original formulation study would then need a reproducible preparation, a relevant incumbent, a defined endpoint and an agreed publication or confidentiality route. Those outputs connect this proposed programme to Bio’s collaboration and study ambitions. They do not create a funded laboratory by being described on a website. The first milestone would be modest and inspectable: one sponsor-reviewed question, a complete comparator brief and a realistic route to qualified execution without diverting resources from the existing flagship work.
The next proposed comparison.
Application-specific microbial evidence and experimental commissioning brief
A decision, not an entire confidential formula.
Scope the opening conversation around a real decision.
An opening discussion can begin with the product category, ingredient class, intended packaging, available evidence and decision that remains unresolved. The proposed output can be scoped before proprietary compositions are exchanged. If confidential detail is needed, the parties would agree an appropriate process and the rights to any future data. A productive discussion might conclude that the existing method is adequate, that a recovery study should come first or that the idea is not worth progressing. The programme earns commercial value by improving that judgement. It would grow through repeatable buyer questions and measured contributions, rather than through a catalogue of unsupported claims.
Microbial material systems · Proposed development discussion
A development path
for this research.
Which microbial uncertainty deserves a defined formulation study?
The people this could serve.Formulation directors, ingredient suppliers and research sponsors.
The decision behind the project.
Your intended application, present alternative and the constraint behind “A formula is also an ecosystem.”. A useful starting point is the change that would justify another development step.
A proposed scope centred on application-specific microbial evidence and experimental commissioning brief.
Agree the comparison, acceptance basis and responsible expertise before discussing a paid package.
Specialist methods and a defined contribution.
Bring relevant analytical or experimental expertise, a comparator suggestion, and the conditions under which your method could resolve this question.
A jointly scoped proposal could connect your contribution with application-specific microbial evidence and experimental commissioning brief.
Define contributions, required access, independent preparations and permitted outputs before work or protected information is shared.
The commercial purpose of the next milestone.
Bring the application or asset thesis, the buyer you expect to value it, and the scientific or commercial uncertainty that must be resolved before another commitment.
The proposed decision record would connect the buyer question with application-specific microbial evidence and experimental commissioning brief. It would identify what a subsequent comparison needs to demonstrate.
Demand, development cost, resources, rights and a decision-changing milestone would need examination. No financing terms or investment outcome are represented here.
What a useful comparison
would record.
- Record logarithmic reduction at specified observation time (dimensionless) with the preparation, method and conditions needed to interpret it.
- Record initial recoverable count (CFU g⁻¹ or CFU mL⁻¹) with the preparation, method and conditions needed to interpret it.
- Record recoverable count after specified time (same units as N_0) with the preparation, method and conditions needed to interpret it.
What the proposed
brief could leave behind.
- Application-specific microbial evidence and experimental commissioning brief
- A preparation, comparator and endpoint record tied to this question.
- A source-linked account of the evidence gaps, study assumptions and next review point.
The proposed discussion brief
A brief you
can take away.
Use non-confidential notes to connect this topic with your own decision. Entries stay in this browser tab; saving creates a text file on your device. Nothing is submitted.
Scoped decision brief, qualified external study design or versioned evidence collection; commercial terms and delivery subject to agreement.
Notes are optional. The brief includes this page’s proposed question and public source links.
Proposed scope; resources, methods, rights and delivery terms would be agreed before work. Begin with non-confidential information.
Sources and reading notes.
External work is identified below. Access notes describe the material inspected for this page; company research questions and proposed work are not presented as findings from these sources.
FDA, n.d.Huang, J. et al. (2024) Bacteriological Analytical Manual, Chapter 23: Methods for Cosmetics. July edition. FDA
Matrix-specific sampling, enumeration, enrichment and identification framework.
Scope and limitations: Official analytical method; not a Bio result, service approval or substitute for jurisdiction-specific product safety assessment.
Open original sourceISO (2019; amendment 2022) ISO 11930, 2019ISO (2019; amendment 2022) ISO 11930: Evaluation of the antimicrobial protection of a cosmetic product
Published standard identity, scope and amendment status.
Scope and limitations: Catalogue abstract only; licensed full standard and amendment not acquired. No acceptance criteria reproduced. Revision is under development.
Open original sourcePinto, D. et al, 2021Pinto, D. et al. (2021) Effect of commonly used cosmetic preservatives on skin resident microflora dynamics. Scientific Reports, 11, 8695
Preparation-specific in vitro preservative comparisons using defined strains and a reconstructed skin model.
Scope and limitations: External model study; no human benefit, Bio efficacy or finished-formula transfer inferred. CC BY 4.0 subject to third-party exceptions.
Open original sourceWang, P. et al, 2025Wang, P. et al. (2025) Microecology in vitro model replicates the human skin microbiome interactions. Nature Communications, 16, 3085
A defined hydrogel-based microecology model, model conditions and available source data.
Scope and limitations: External in vitro model; not a clinical study or Bio platform. Source XLSX identified but not numerically extracted in this authoring pass.
Open original source